<p>投资低于 10 美元的便宜股票具有很大吸引力。其中一个好处是低股价使您能够用较少的资金购买更多股票。如果股价大幅上涨，即使是小幅百分比的增长也可以转化为投资回报的大幅提升。</p>
<p>低价股往往比成熟公司更容易波动。低于 10 美元的便宜股票通常属于这一类别。这可能存在风险，但一些投资者被潜在的快速利润吸引，这些利润来自于正确把握市场时机。</p>
<p>不幸的是，低于 10 美元的便宜股票往往来自于具有有限业绩记录、未经验证的商业模式或财务困难历史的公司。这使它们比成熟公司的股票更加风险。然而，本文讨论的股票都受益于强劲的营收增长，更重要的是，有盈利。这使它们比绝大多数低价股更加财务稳定。让我们看看这些公司及其股票。</p>
<h2>DLocal (DLO)</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源: Wirestock Creators / Shutterstock.com</p>
<p><strong>DLocal</strong> (纳斯达克：<strong>DLO</strong>) 是一家运营支付处理平台的公司，帮助在国际市场，尤其是新兴市场运营的企业接受客户支付。随着金融科技股机会不断增长和带来更多消费者上网的机会，这使得它特别具有吸引力。</p>
<p>DLocal 允许商家在他们运营的国家接受各种本地支付方式。这可以包括通过便利店现金支付、银行转账、移动钱包和本地借记卡等支付选项。从高层次上看，DLocal 是国际企业和新兴市场客户之间的桥梁。</p>
<p>第一季度支付总额增长了 49%。尽管增长迅速，但较预期较弱的收益使股价下跌。这很好地代表了投资者未来对 DLocal 的预期：强劲的营收增长，但盈利停滞，预计要到 2025 年才会改善。</p>
<p>它仍然为股东提供收益，增长速度超过 30%，并且可以合理地翻倍。这使得 DLO 股票具有潜在突破的价值。</p>
<h2>Fennec Pharmaceuticals (FENC)</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源: Billion Photos / Shutterstock</p>
<p><strong>Fennec Pharmaceuticals</strong> (纳斯达克：<strong>FENC</strong>) 是一家处于收入阶段的生物制药股票，具有快速增长的潜力。目前股价为 6.30 美元，但两位分析师认为其价值分别为 15 美元和 17 美元。</p>
<p>该公司称其主要候选药物为 PEDMARK。医生指出，它可预防接受化疗的儿童听力损失。化疗可能导致接受治疗局部、非转移性实体肿瘤的小儿患者听力损失。</p>
<p>这是唯一获得 FDA 批准用于减少儿童化疗患者听力损失风险的疗法。</p>
<p>Fennec Pharmaceuticals 与 Norgine 签订了独家许可协议，以在欧洲、澳大利亚和新西兰商业化 PEDMARQSI，这是 PEDMARK 在这些地区的同义商标。该公司从该交易中获得了约 4320 万美元，并有可能获得高达约 2.3 亿美元的额外商业和监管里程碑。</p>
<p>该公司在最近一个季度末拥有超过 5100 万美元现金，并总体上产生盈利。</p>
<h2>Direct Digital Holdings (DRCT)</h2>
<p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="1" height="1" original-src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>来源: weedezign via Shutterstock</p>
<p><strong>Direct Digital Holdings</strong> (纳斯达克：<strong>DRCT</strong>) 是另一家低于 10 美元的高风险、高回报股票，具有爆发潜力。该公司提供广告服务，在 2024 年经历了起起落落。股价目前为 4 美元左右，在 3 月份飙升至 33 美元以上后有所下跌。</p>
<p>导致急剧下跌的原因很简单：Direct Digital Holdings 未能达到预期的收入和盈利。预计收入将接近 6600 万美元，但实际只有 4101 万美元。这导致每股盈利为-0.08 美元，而预期为 26 美分。</p>
<p>由于这一结果，该公司还大幅调整了其 2024 年的整体展望。该公司现在预计今年销售额为 1.8 亿美元，低于之前的 2.426 亿美元。大多数指标表明 DRCT 股票目前定价合理。</p>
<p>今年的收入预计将翻番，盈利增长预计将接近 50%。这次修正为大胆的投资者提供了机会。</p>
<p>_在本文发布日期，Alex Sirois 在本文中提到的证券中没有（直接或间接）任何头寸。本文中表达的观点属于作者本人，遵守 InvestorPlace.com 的发布指南。</p>
<p><em>在本文发布日期，负责编辑在本文中提到的证券中没有（直接或间接）任何头寸。</em></p>
<p>Alex Sirois 是 InvestorPlace 的自由撰稿人，他的个人股票投资风格侧重于长期持有、积累财富的股票选择。他曾在从电子商务到翻译再到教育等多个行业工作，并利用他在乔治华盛顿大学获得的工商管理硕士学位，通过这些技能过滤他的写作。</p>

DRCT

<p>投资于股价低于 10 美元的便宜股票具有吸引力，因为有可能获得巨大回报。然而，这些股票通常存在风险，并来自具有有限业绩记录的公司。尽管如此，DLocal、Fennec Pharmaceuticals 和 Direct Digital Holdings 这三支股票显示出潜力。DLocal 经营支付处理平台，具有强劲的营收增长。Fennec Pharmaceuticals 拥有获得 FDA 批准的疗法，具有快速增长的潜力。Direct Digital Holdings 提供广告服务，具有高风险、高回报的潜力</p>

<p>Investing in dirt cheap stocks under $10 has a lot of appeal. One of the benefits is that a low share price allows you to buy more shares with a smaller amount of money. If the stock price increases significantly, even a small percentage gain can translate to a large return on your investment.</p>
<div class="lb-trans"><p>投资低于 10 美元的便宜股票具有很大吸引力。其中一个好处是低股价使您能够用较少的资金购买更多股票。如果股价大幅上涨，即使是小幅百分比的增长也可以转化为投资回报的大幅提升。</p>
</div><p>Penny stocks tend to be more volatile than established companies. Cheap stocks under $10 often fall into this category. This can be risky, but some investors are drawn to the potential for quick profits that result from timing the market correctly.</p>
<div class="lb-trans"><p>低价股往往比成熟公司更容易波动。低于 10 美元的便宜股票通常属于这一类别。这可能存在风险，但一些投资者被潜在的快速利润吸引，这些利润来自于正确把握市场时机。</p>
</div><p>Unfortunately, cheap stocks under $10 are often from companies with limited track records, unproven business models, or a history of financial difficulties. This makes them much riskier than stocks from established companies. However, the stocks discussed in this article all benefit from strong revenue growth and, more importantly, positive net earnings. That makes them more financially stable than the vast majority of penny stocks. Let’s take a look at those firms and their stocks.</p>
<div class="lb-trans"><p>不幸的是，低于 10 美元的便宜股票往往来自于具有有限业绩记录、未经验证的商业模式或财务困难历史的公司。这使它们比成熟公司的股票更加风险。然而，本文讨论的股票都受益于强劲的营收增长，更重要的是，有盈利。这使它们比绝大多数低价股更加财务稳定。让我们看看这些公司及其股票。</p>
</div><h2>DLocal (DLO)</h2>
<div class="lb-trans"><h2>DLocal (DLO)</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Wirestock Creators / Shutterstock.com</p>
<div class="lb-trans"><p>来源: Wirestock Creators / Shutterstock.com</p>
</div><p><strong>DLocal</strong> (NASDAQ:<strong>DLO</strong>) operates a payment processing platform that helps businesses operating in international markets, especially emerging markets, accept payments from customers. That makes it especially attractive as the fintech stock opportunity continues to gain momentum and opportunities to bring more consumers online increase.</p>
<div class="lb-trans"><p><strong>DLocal</strong> (纳斯达克：<strong>DLO</strong>) 是一家运营支付处理平台的公司，帮助在国际市场，尤其是新兴市场运营的企业接受客户支付。随着金融科技股机会不断增长和带来更多消费者上网的机会，这使得它特别具有吸引力。</p>
</div><p>DLocal allows merchants to accept a wide range of local payment methods in the countries they operate in. It can include payment options like cash payments through convenience stores, bank transfers, mobile wallets, and local debit cards, among others. At a high level, DLocal is a bridge between international businesses and customers in emerging markets.</p>
<div class="lb-trans"><p>DLocal 允许商家在他们运营的国家接受各种本地支付方式。这可以包括通过便利店现金支付、银行转账、移动钱包和本地借记卡等支付选项。从高层次上看，DLocal 是国际企业和新兴市场客户之间的桥梁。</p>
</div><p>Total payment volume grew by 49% in the first quarter. Despite that rapid growth, weaker-than-anticipated earnings sent shares downward. That’s a fair representation of what investors should expect from DLocal moving forward: strong top-line growth but stagnant earnings that aren’t expected to improve until 2025.</p>
<div class="lb-trans"><p>第一季度支付总额增长了 49%。尽管增长迅速，但较预期较弱的收益使股价下跌。这很好地代表了投资者未来对 DLocal 的预期：强劲的营收增长，但盈利停滞，预计要到 2025 年才会改善。</p>
</div><p>It still provides earnings to shareholders, is growing well above 30%, and can reasonably double in price. That makes DLO stock worthwhile as it harbors breakout potential.</p>
<div class="lb-trans"><p>它仍然为股东提供收益，增长速度超过 30%，并且可以合理地翻倍。这使得 DLO 股票具有潜在突破的价值。</p>
</div><h2>Fennec Pharmaceuticals (FENC)</h2>
<div class="lb-trans"><h2>Fennec Pharmaceuticals (FENC)</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: Billion Photos / Shutterstock</p>
<div class="lb-trans"><p>来源: Billion Photos / Shutterstock</p>
</div><p><strong>Fennec Pharmaceuticals</strong> (NASDAQ:<strong>FENC</strong>) is a revenue stage biopharmaceutical stock with the potential to grow rapidly. Shares currently trade for $6.30 but the two analysts covering the equity believe it is worth $15 and $17, respectively.</p>
<div class="lb-trans"><p><strong>Fennec Pharmaceuticals</strong> (纳斯达克：<strong>FENC</strong>) 是一家处于收入阶段的生物制药股票，具有快速增长的潜力。目前股价为 6.30 美元，但两位分析师认为其价值分别为 15 美元和 17 美元。</p>
</div><p>The company calls its leading candidate drug PEDMARK. Doctors indicate it to prevent hearing loss in children undergoing chemotherapy. Chemotherapy can cause hearing loss in pediatric patients undergoing treatment for localized, non-metastatic, solid tumors.</p>
<div class="lb-trans"><p>该公司称其主要候选药物为 PEDMARK。医生指出，它可预防接受化疗的儿童听力损失。化疗可能导致接受治疗局部、非转移性实体肿瘤的小儿患者听力损失。</p>
</div><p>It is the only FDA-approved therapy indicated to reduce the risk of hearing loss associated with chemotherapy in pediatric patients.</p>
<div class="lb-trans"><p>这是唯一获得 FDA 批准用于减少儿童化疗患者听力损失风险的疗法。</p>
</div><p>Fennec Pharmaceuticals executed an exclusive licensing agreement with Norgine to commercialize PEDMARQSI, a synonymous trade name for PEDMARK in Europe, Australia, and New Zealand. The firm received approximately $43.2 million from that deal and has the potential to receive up to approximately $230 million in additional commercial and regulatory milestones.</p>
<div class="lb-trans"><p>Fennec Pharmaceuticals 与 Norgine 签订了独家许可协议，以在欧洲、澳大利亚和新西兰商业化 PEDMARQSI，这是 PEDMARK 在这些地区的同义商标。该公司从该交易中获得了约 4320 万美元，并有可能获得高达约 2.3 亿美元的额外商业和监管里程碑。</p>
</div><p>The company had more than $51 million in cash at the end of the most recent quarter and is producing earnings overall.</p>
<div class="lb-trans"><p>该公司在最近一个季度末拥有超过 5100 万美元现金，并总体上产生盈利。</p>
</div><h2>Direct Digital Holdings (DRCT)</h2>
<div class="lb-trans"><h2>Direct Digital Holdings (DRCT)</h2>
</div><p><img src="https://imageproxy.pbkrs.com/https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif" alt="" original-src="https://investorplace.com/wp-content/plugins/lazy-load/images/1x1.trans.gif"/></p>
<p>Source: weedezign via Shutterstock</p>
<div class="lb-trans"><p>来源: weedezign via Shutterstock</p>
</div><p><strong>Direct Digital Holdings</strong> (NASDAQ:<strong>DRCT</strong>) is another high-risk, high-reward stock under $10 with the potential to explode. The company provides advertising services and has been up and down in 2024. Shares currently trade for $4 and change after soaring above $33 in March.</p>
<div class="lb-trans"><p><strong>Direct Digital Holdings</strong> (纳斯达克：<strong>DRCT</strong>) 是另一家低于 10 美元的高风险、高回报股票，具有爆发潜力。该公司提供广告服务，在 2024 年经历了起起落落。股价目前为 4 美元左右，在 3 月份飙升至 33 美元以上后有所下跌。</p>
</div><p>The reason for the sharp decline was straightforward: Direct Digital Holdings missed revenue and earnings expectations by a wide margin. Revenues were anticipated to approach $66 million but came in well short at $41.01 million. That led to a -$0.08 EPS, whereas 26 cents had been expected.</p>
<div class="lb-trans"><p>导致急剧下跌的原因很简单：Direct Digital Holdings 未能达到预期的收入和盈利。预计收入将接近 6600 万美元，但实际只有 4101 万美元。这导致每股盈利为-0.08 美元，而预期为 26 美分。</p>
</div><p>The company also readjusted its overall 2024 outlook sharply as a result. The company now anticipates $180 million in sales this year, down from $242.6 million previously. Most metrics suggest that DRCT shares are currently priced right.</p>
<div class="lb-trans"><p>由于这一结果，该公司还大幅调整了其 2024 年的整体展望。该公司现在预计今年销售额为 1.8 亿美元，低于之前的 2.426 亿美元。大多数指标表明 DRCT 股票目前定价合理。</p>
</div><p>Revenues are on track to more than double this year and earnings growth is expected to approach 50%. The correction is an opportunity for brazen investors.</p>
<div class="lb-trans"><p>今年的收入预计将翻番，盈利增长预计将接近 50%。这次修正为大胆的投资者提供了机会。</p>
</div><p><em>On the date of publication, Alex Sirois did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em> <em>Publishing Guidelines</em> <em>.</em></p>
<div class="lb-trans"><p>_在本文发布日期，Alex Sirois 在本文中提到的证券中没有（直接或间接）任何头寸。本文中表达的观点属于作者本人，遵守 InvestorPlace.com 的发布指南。</p>
</div><p><em>On the date of publication, the responsible editor did not have (either directly or</em></p>
<p><em>indirectly) any positions in the securities mentioned in this article.</em></p>
<div class="lb-trans"><p><em>在本文发布日期，负责编辑在本文中提到的证券中没有（直接或间接）任何头寸。</em></p>
</div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p>
<div class="lb-trans"><p>Alex Sirois 是 InvestorPlace 的自由撰稿人，他的个人股票投资风格侧重于长期持有、积累财富的股票选择。他曾在从电子商务到翻译再到教育等多个行业工作，并利用他在乔治华盛顿大学获得的工商管理硕士学位，通过这些技能过滤他的写作。</p>
</div>

3 只价格低于 10 美元的超便宜股票可能会大涨！